Key result
Aspirin therapy in low-risk patients with nonvalvular atrial fibrillation resulted in a primary event rate of 2.2% per year (95% CI, 1.6%-3.0%) for ischemic stroke and systemic embolism.
Why the study?
Does aspirin 325 mg/d result in low rates of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation categorized as low risk?
Population
892 patients with nonvalvular atrial fibrillation categorized as 'low risk' based on the absence of 4…
Design
Cohort
Follow-up
mean 2.0 years
Authors
Loading...
Supports aspirin in scheme-identified low-risk nonvalvular AF; leaves open randomized confirmation of net clinical benefit.
Cohort (n=892)
Yes
Does aspirin 325 mg/d result in low rates of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation categorized as low risk?
A specific risk stratification scheme can reliably identify patients with nonvalvular atrial fibrillation who have low rates of ischemic stroke when treated with aspirin.
The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators (1998) conducted a cohort in Nonvalvular atrial fibrillation (n=892). Aspirin was evaluated on Ischemic stroke and systemic embolism (95% CI 1.6%-3.0%). Aspirin therapy in low-risk patients with nonvalvular atrial fibrillation resulted in a primary event rate of 2.2% per year (95% CI, 1.6%-3.0%) for ischemic stroke and systemic embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: